Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease

U. Ritthaler, Y. Deng, Y. Zhang, J. Greten, M. Abel, B. Sido, J. Allenberg, G. Otto, H. Roth, A. Bierhaus, R. Ziegler, A. M. Schmidt, R. Waldherr, P. Wahl, David Stern, P. P. Nawroth

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

The cellular interactions of advanced glycation end products (AGEs), which have been hypothesized to contribute to the development of vascular lesions, occur, at least tn part, through their binding to a novel integral membrane protein, the receptor for AGEs (RAGE). Studies of human vascular segments show that endothelial RAGE expression at the antigen and mRNA level was variable and usually at low levels in samples from healthy individuals. In contrast, patients with a range of peripheral occlusive vascular diseases, with or without underlying diabetes, demonstrated prominent enhancement of endothelial RAGE expression. Smooth muscle cells and nerves in the vessel wall showed constitutively high levels of RAGE expression that were unchanged with aging (from 1 to 92 years) or by the presence of vascular disease. These data suggest that RAGE is likely to have ligands other than AGEs, and that multiple factors in addition to AGEs impact on its expression. Taken together, our findings suggest that RAGE may contribute to the pathogenesis of a range of vascular disorders.

Original languageEnglish (US)
Pages (from-to)688-694
Number of pages7
JournalAmerican Journal of Pathology
Volume146
Issue number3
StatePublished - Jan 1 1995

Fingerprint

Peripheral Vascular Diseases
Blood Vessels
Advanced Glycosylation End Products
Vascular Diseases
Smooth Muscle Myocytes
Advanced Glycosylation End Product-Specific Receptor
Membrane Proteins
Ligands
Antigens
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Ritthaler, U., Deng, Y., Zhang, Y., Greten, J., Abel, M., Sido, B., ... Nawroth, P. P. (1995). Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. American Journal of Pathology, 146(3), 688-694.

Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. / Ritthaler, U.; Deng, Y.; Zhang, Y.; Greten, J.; Abel, M.; Sido, B.; Allenberg, J.; Otto, G.; Roth, H.; Bierhaus, A.; Ziegler, R.; Schmidt, A. M.; Waldherr, R.; Wahl, P.; Stern, David; Nawroth, P. P.

In: American Journal of Pathology, Vol. 146, No. 3, 01.01.1995, p. 688-694.

Research output: Contribution to journalArticle

Ritthaler, U, Deng, Y, Zhang, Y, Greten, J, Abel, M, Sido, B, Allenberg, J, Otto, G, Roth, H, Bierhaus, A, Ziegler, R, Schmidt, AM, Waldherr, R, Wahl, P, Stern, D & Nawroth, PP 1995, 'Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease', American Journal of Pathology, vol. 146, no. 3, pp. 688-694.
Ritthaler U, Deng Y, Zhang Y, Greten J, Abel M, Sido B et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. American Journal of Pathology. 1995 Jan 1;146(3):688-694.
Ritthaler, U. ; Deng, Y. ; Zhang, Y. ; Greten, J. ; Abel, M. ; Sido, B. ; Allenberg, J. ; Otto, G. ; Roth, H. ; Bierhaus, A. ; Ziegler, R. ; Schmidt, A. M. ; Waldherr, R. ; Wahl, P. ; Stern, David ; Nawroth, P. P. / Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. In: American Journal of Pathology. 1995 ; Vol. 146, No. 3. pp. 688-694.
@article{af6689f5690f49158bd155f794d4db9d,
title = "Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease",
abstract = "The cellular interactions of advanced glycation end products (AGEs), which have been hypothesized to contribute to the development of vascular lesions, occur, at least tn part, through their binding to a novel integral membrane protein, the receptor for AGEs (RAGE). Studies of human vascular segments show that endothelial RAGE expression at the antigen and mRNA level was variable and usually at low levels in samples from healthy individuals. In contrast, patients with a range of peripheral occlusive vascular diseases, with or without underlying diabetes, demonstrated prominent enhancement of endothelial RAGE expression. Smooth muscle cells and nerves in the vessel wall showed constitutively high levels of RAGE expression that were unchanged with aging (from 1 to 92 years) or by the presence of vascular disease. These data suggest that RAGE is likely to have ligands other than AGEs, and that multiple factors in addition to AGEs impact on its expression. Taken together, our findings suggest that RAGE may contribute to the pathogenesis of a range of vascular disorders.",
author = "U. Ritthaler and Y. Deng and Y. Zhang and J. Greten and M. Abel and B. Sido and J. Allenberg and G. Otto and H. Roth and A. Bierhaus and R. Ziegler and Schmidt, {A. M.} and R. Waldherr and P. Wahl and David Stern and Nawroth, {P. P.}",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "146",
pages = "688--694",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease

AU - Ritthaler, U.

AU - Deng, Y.

AU - Zhang, Y.

AU - Greten, J.

AU - Abel, M.

AU - Sido, B.

AU - Allenberg, J.

AU - Otto, G.

AU - Roth, H.

AU - Bierhaus, A.

AU - Ziegler, R.

AU - Schmidt, A. M.

AU - Waldherr, R.

AU - Wahl, P.

AU - Stern, David

AU - Nawroth, P. P.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The cellular interactions of advanced glycation end products (AGEs), which have been hypothesized to contribute to the development of vascular lesions, occur, at least tn part, through their binding to a novel integral membrane protein, the receptor for AGEs (RAGE). Studies of human vascular segments show that endothelial RAGE expression at the antigen and mRNA level was variable and usually at low levels in samples from healthy individuals. In contrast, patients with a range of peripheral occlusive vascular diseases, with or without underlying diabetes, demonstrated prominent enhancement of endothelial RAGE expression. Smooth muscle cells and nerves in the vessel wall showed constitutively high levels of RAGE expression that were unchanged with aging (from 1 to 92 years) or by the presence of vascular disease. These data suggest that RAGE is likely to have ligands other than AGEs, and that multiple factors in addition to AGEs impact on its expression. Taken together, our findings suggest that RAGE may contribute to the pathogenesis of a range of vascular disorders.

AB - The cellular interactions of advanced glycation end products (AGEs), which have been hypothesized to contribute to the development of vascular lesions, occur, at least tn part, through their binding to a novel integral membrane protein, the receptor for AGEs (RAGE). Studies of human vascular segments show that endothelial RAGE expression at the antigen and mRNA level was variable and usually at low levels in samples from healthy individuals. In contrast, patients with a range of peripheral occlusive vascular diseases, with or without underlying diabetes, demonstrated prominent enhancement of endothelial RAGE expression. Smooth muscle cells and nerves in the vessel wall showed constitutively high levels of RAGE expression that were unchanged with aging (from 1 to 92 years) or by the presence of vascular disease. These data suggest that RAGE is likely to have ligands other than AGEs, and that multiple factors in addition to AGEs impact on its expression. Taken together, our findings suggest that RAGE may contribute to the pathogenesis of a range of vascular disorders.

UR - http://www.scopus.com/inward/record.url?scp=0028919426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028919426&partnerID=8YFLogxK

M3 - Article

VL - 146

SP - 688

EP - 694

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -